Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 9 Next > New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer December 06, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations November 29, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences November 15, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022 November 03, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients November 02, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease November 01, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Third Quarter 2022 Financial Results October 27, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities October 24, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers October 20, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022 October 18, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma October 17, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies October 17, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD MGNX Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022 October 13, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer October 11, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product October 03, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines September 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Completes Acquisition of MiroBio September 20, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma September 16, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19 September 16, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline September 15, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity September 13, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study September 07, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) September 06, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status September 04, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences August 29, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022 August 29, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option August 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care August 17, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Acquire Remaining Worldwide Rights of Trodelvy® August 15, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study August 15, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.